Have you or someone you love been diagnosed with Alzheimer’s disease? This clinical trial may be just what you.

End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 ...

A recent population-based study published in the Journal of American Medical Association identified a modest increase in ...

Regular walking emerges as a potent strategy against dementia and heart disease, especially for older adults in India, where ...

Dementia is often associated with memory loss, but one of the earliest signs can actually be much more subtle.

Recent research highlights carnosic acid, found in rosemary and sage, as a potential weapon against Alzheimer's. Scientists ...

It’s worth noting that the study suggests moderate-to-vigorous physical activity to reap its potential dementia-beating effects. That means one can’t just go slow and easy; the heart has to get ...

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

A new study published in the journal Neurology has found that drinking alcohol, even in relatively moderate amounts, ...

Moderate Alzheimer's disease is characterized by increasingly poor memory and judgment, deepening confusion, getting lost, and mixing up who people are.

In this uncontrolled environment, the pathological cascade of Alzheimer’s begins, with the formation of beta-amyloid protein ...